Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients

Journal of Alzheimer's Disease

Volumn 33, Issue 4, 2013, Pages 929-939

  Choo, Il Han ^a,b   Ni, Ruiqing ^a   Schöll, Michael ^a   Wall, Anders ^c   Almkvist, Ove ^d   Nordberg, Agneta ^a,e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Chosun University College of Medicine   (South Korea)

^c UPPSALA UNIVERSITY   (Sweden)

^d STOCKHOLM UNIVERSITY   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biomarkers; combination; mild cognitive impairment; predictor

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; FLUORODEOXYGLUCOSE F 18; GLUCOSE; TAU PROTEIN; BIOLOGICAL MARKER; DIAGNOSTIC AGENT;

ADULT; ALLELE; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; DISEASE COURSE; FEMALE; FOLLOW UP; GENOTYPE; GLUCOSE METABOLISM; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; AGED; LONGITUDINAL STUDY; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PREDICTIVE VALUE; PSYCHOLOGICAL ASPECT; SCINTISCANNING; STANDARD;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS;

EID: 84873688730     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-121489     Document Type: Article

References (49)

1. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65, 1509-1517
2. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC (2006) [11C] PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 67, 446-452
3. Oh H, Madison C, Haight TJ, Markley C, Jagust WJ (2012) Effects of age and beta-Amyloid on cognitive changes in normal elderly people. Neurobiol Aging 33, 2746-2755
4. Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 45, 358-368
5. Frisoni GB, Hampel H, O'Brien JT, Ritchie K, Winblad B (2011) Revised criteria for Alzheimer's disease: What are the lessons for clinicians? Lancet Neurol 10, 598-601
6. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 280-292
7. Ewers M,Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR Jr, Feldman HH, Bokde AL, Alexander GE, Scheltens P, Vellas B, Dubois B, Weiner M, Hampel H (2012) Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging 33, 1203-1214 e1202
8. Fjell AM,Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, Brewer JB, Dale AM (2010) CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J Neurosci 30, 2088-2101
9. Gomar JJ, Bobes-Bascaran MT, Conejero-Goldberg C, Davies P, Goldberg TE (2011) Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. Arch Gen Psychiatry 68, 961-969
10. Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR Jr, Weiner MW, Jagust WJ (2010) Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75, 230-238
11. Vos S, van Rossum I, Burns L, Knol D, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Handels R, L'Italien G, van der FlierW, Aalten P, Teunissen C, Barkhof F, BlennowK,Wolz R, Rueckert D,Verhey F,Visser PJ (2012) Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol Aging 33, 2272-2281
12. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56, 303-308
13. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment-beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256, 240-246
14. American PA (1994) Diagnostic and statistical manual of mental disorders: DSM-IV (4th ed.), American Psychiatric Association, Washington, D.C.
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944
16. Ostertag H, Kubler WK, Doll J, Lorenz WJ (1989) Measured attenuation correction methods. Eur J Nucl Med 15, 722-726
17. Patlak CS, Blasberg RG, Fenstermacher JD (1983) Graphical evaluation of blood-To-brain transfer constants from multipletime uptake data. J Cereb Blood Flow Metab 3, 1-7
18. Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, Mitchell TN, Brooks DJ, Duncan JS (2003) Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp 19, 224-247
19. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K (1999) Cerebrospinal fluid beta-Amyloid(1-42) in Alzheimer disease: Differences between early-And late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56, 673-680
20. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease?. Mol Chem Neuropathol 26, 231-245
21. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, Andreasen N, Blennow K (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285, 49-52
22. Almkvist O, Tallberg IM (2009) Cognitive decline from estimated premorbid status predicts neurodegeneration in Alzheimer's disease. Neuropsychology 23, 117-124
23. Bergman I, BlombergM, Almkvist O (2007) The importance of impaired physical health and age in normal cognitive aging. Scand J Psychol 48, 115-125
24. Hosmer D (1989) Applied Logistic Regression, JohnWiley &Sons, Toronto
25. Schmand B, Huizenga HM, van Gool WA (2010) Metaanalysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease. Psychol Med 40, 135-145
26. Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, Glodzik-Sobanska L, De Santi S, Zinkowski R, Mehta P, Pratico D, Saint Louis LA,Wallin A, Blennow K, de Leon MJ (2009) Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging 30, 682-690
27. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O (2012) Cerebrospinal fluid levels of beta-Amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69, 98-106
28. Mattsson N, Portelius E, Rolstad S, Gustavsson M, Andreasson U, Stridsberg M, Wallin A, Blennow K, Zetterberg H (2012) Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. J Alzheimers Dis 30, 767-778
29. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA302, 385-393
30. Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G,DeCarlo C, Padiglioni C, Mastrocola S, LisettiV, Calabresi P (2012) Performance of abeta1-40, abeta1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. J Alzheimers Dis 29, 229-238
31. Wallin A, Gothlin M, Gustavsson M, Zetterberg H, Eckerstrom C, Blennow K, Edman A, Lind K, Nordlund A, Rolstad S (2011) Progression from mild to pronouncedMCIis not associated with cerebrospinal fluid biomarker deviations. Dement Geriatr Cogn Disord 32, 193-197
32. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Burger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K (2009) Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. Lancet Neurol 8, 619-627
33. Hort J, Bartos A, Pirttila T, Scheltens P (2010) Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. Eur J Neurol 17, 90-96
34. Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK (2011) Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology 77, 1619-1628
35. Anchisi D, Borroni B, Franceschi M, Kerrouche N, Kalbe E, Beuthien-Beumann B, Cappa S, Lenz O, Ludecke S, Marcone A, Mielke R, Ortelli P, Padovani A, Pelati O, Pupi A, Scarpini E, Weisenbach S, Herholz K, Salmon E, Holthoff V, Sorbi S, Fazio F, Perani D (2005) Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 62, 1728-1733
36. Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, Minoshima S, Schwaiger M, Kurz A (2005) Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 46, 1625-1632
37. Fouquet M, Desgranges B, Landeau B, Duchesnay E, Mezenge F, de la Sayette V, Viader F, Baron JC, Eustache F, ChetelatG(2009) Longitudinal brain metabolic changes from amnestic mild cognitive impairment to Alzheimer's disease. Brain 132, 2058-2067
38. Herholz K, Westwood S, Haense C, Dunn G (2011) Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. J Nucl Med 52, 1218-1226
39. Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, Salmon E, Baron JC, De Cristofaro MT, Padovani A, Borroni B, Franceschi M, Bracco L, Pupi A (2004) MCI conversion to dementia and the APOE genotype: A prediction study with FDG-PET. Neurology 63, 2332-2340
40. Mosconi L, Tsui WH, Pupi A, De Santi S, Drzezga A, Minoshima S, de LeonMJ(2007) (18)F-FDGPETdatabase of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease. J Nucl Med 48, 1129-1134
41. Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, Hyman BT, Crain B, Tang MX, Phelps CH (1998) Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med 338, 506-511
42. Ohara T, Ninomiya T, Kubo M, Hirakawa Y, Doi Y, Hata J, Iwaki T, Kanba S, Kiyohara Y (2011) Apolipoprotein genotype for prediction of Alzheimer's disease in older Japanese: The Hisayama Study. J Am Geriatr Soc 59, 1074-1079
43. Devanand DP, Liu X, Tabert MH, Pradhaban G, Cuasay K, Bell K, de Leon MJ, Doty RL, Stern Y, Pelton GH (2008) Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. Biol Psychiatry 64, 871-879
44. Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack CR Jr, Aisen PS, Thal LJ (2008) Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology 70, 191-199
45. Lee DY, Youn JC, Choo IH, Kim KW, Jhoo JH, Pak YS, Suh KW, Woo JI (2006) Combination of clinical and neuropsychologic information as a better predictor of the progression to Alzheimer disease in questionable dementia individuals. Am J Geriatr Psychiatry 14, 130-138
46. Sarazin M, Berr C, De Rotrou J, Fabrigoule C, Pasquier F, Legrain S, Michel B, Puel M, Volteau M, Touchon J, Verny M, Dubois B (2007) Amnestic syndrome of the medial temporal type identifies prodromal AD: A longitudinal study. Neurology 69, 1859-1867
47. Tabert MH, Manly JJ, Liu X, Pelton GH, Rosenblum S, Jacobs M, Zamora D, Goodkind M, Bell K, Stern Y, Devanand DP (2006) Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. Arch Gen Psychiatry 63, 916-924
48. Koivunen J, Scheinin N,Virta JR, Aalto S,Vahlberg T, Nagren K, Helin S, Parkkola R,Viitanen M, Rinne JO (2011) Amyloid PET imaging in patients with mild cognitive impairment: A 2-year follow-up study. Neurology 76, 1085-1090
49. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Nagren K, Bullock R,Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ (2009) Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study. Neurology 73, 754-760